Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease
Abstract Background Nicotinamide, a form of B3 vitamin, is an NAD+ precursor that reduces pTau231 levels via histone deacetylase inhibition in murine models of Alzheimer’s disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of earl...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-025-01693-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|